Egrifta (Tesamorelin) History and Development

The Clinical Problem That Drove Development

HIV-associated lipodystrophy emerged as a recognized complication of antiretroviral therapy (ART) in the late 1990s, characterized by abnormal fat redistribution, particularly the accumulation of visceral adipose tissue (VAT). Patients on protease inhibitor-based regimens showed the highest prevalence, estimated at 20% to 35% in cross-sectional surveys [1]. This was not a cosmetic concern. Excess VAT correlated with insulin resistance, dyslipidemia, and elevated cardiovascular risk in the HIV population [2].

Before tesamorelin, clinicians had no FDA-approved pharmacotherapy targeting HIV-associated visceral fat accumulation. Switching ART regimens produced inconsistent results. Growth hormone (recombinant hGH, trade name Serostim) was approved for HIV-associated wasting, not lipodystrophy, and its supraphysiologic dosing caused frequent side effects including arthralgias and glucose intolerance [3]. The field needed a therapy that could reduce VAT without imposing the metabolic penalties of exogenous GH at pharmacologic doses.

That gap defined the development thesis for tesamorelin. Rather than administering GH directly, Theratechnologies pursued a growth hormone-releasing hormone analog that would stimulate the pituitary to secrete GH in a more physiologic, pulsatile pattern. The hypothesis: restore the GH axis upstream, reduce VAT downstream, and avoid the adverse-effect profile of direct GH injection.

Peptide Chemistry and Design

Tesamorelin is a 44-amino-acid peptide identical in sequence to endogenous human GHRH(1-44)-NH2, with one structural modification. A trans-3-hexenoic acid (THA) group is conjugated to the tyrosine residue at position 1 via the amino terminus [4]. That single change matters. It extends the peptide's half-life by conferring partial resistance to dipeptidyl peptidase IV (DPP-IV), the enzyme that rapidly cleaves native GHRH between positions 2 and 3 in vivo.

Native GHRH(1-44) has a plasma half-life of roughly 6 to 8 minutes. The THA modification allowed tesamorelin to achieve sufficient bioavailability after subcutaneous injection to produce a clinically meaningful GH pulse [4]. The peptide retains full agonist activity at the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. Binding triggers a Gs-protein-coupled signaling cascade, activating adenylyl cyclase, raising intracellular cyclic AMP, and opening voltage-gated calcium channels. The result is GH granule exocytosis.

This approach preserves negative feedback. As GH and insulin-like growth factor 1 (IGF-1) levels rise, somatostatin release from the hypothalamus increases, dampening further GH secretion. The pulsatile pattern of GH release is maintained rather than overridden, a key pharmacologic distinction from exogenous GH administration [5].

Preclinical and Early Clinical Work

Theratechnologies, a biopharmaceutical company founded in 1993 in Montreal, began developing tesamorelin (then designated TH9507) in the early 2000s. Early-phase pharmacokinetic studies in healthy volunteers established that a single 2 mg subcutaneous dose produced a GH peak approximately 30 to 60 minutes post-injection, with GH levels returning to baseline within 4 to 6 hours [4]. This confirmed the pulsatile secretion profile the developers intended.

Phase 1/2 dose-ranging work in HIV-positive patients with lipodystrophy tested doses from 1 mg to 2 mg daily over 12 weeks. The 2 mg dose emerged as the target based on VAT reduction measured by CT scan at the L4-L5 vertebral level, the standard imaging endpoint for abdominal adiposity trials [6]. IGF-1 levels rose proportionally, confirming downstream GH axis activation. Safety signals were manageable: injection-site reactions, peripheral edema, and arthralgias were the most common findings, all consistent with GH-pathway pharmacology.

Key Phase 3 Trials

The Falutz et al. (2007) Study

The landmark trial, published in the New England Journal of Medicine by Jean Falutz and colleagues in November 2007, was a multicenter, randomized, double-blind, placebo-controlled study enrolling 412 HIV-infected adults with excess abdominal fat (waist circumference >95 cm for men, >94 cm for women) [1]. Participants received tesamorelin 2 mg or placebo subcutaneously once daily for 26 weeks.

The primary endpoint was percent change in trunk fat measured by CT. Results were clear. The tesamorelin group showed a 15.2% mean reduction in VAT from baseline compared with a 5.0% mean increase in the placebo group (P<0.001) [1]. In absolute terms, tesamorelin patients lost approximately 27.6 cm² of visceral fat area at the L4-L5 level.

Secondary endpoints supported the primary finding. Trunk fat-to-limb fat ratio improved. Patient-reported body image distress scores improved. IGF-1 levels rose by a mean of 81% in the treatment group. Lipid parameters showed a modest but statistically significant reduction in triglycerides (a mean decrease of 50 mg/dL) and non-HDL cholesterol [1].

Dr. Jean Falutz of the McGill University Health Centre summarized the clinical significance: "For the first time, we have a therapy that selectively reduces visceral fat accumulation in HIV-infected patients without the metabolic side effects associated with pharmacologic doses of growth hormone" [1].

The Confirmatory Phase 3 Study

A second phase 3 trial, also led by Falutz and colleagues and published in the Journal of Clinical Endocrinology & Metabolism in 2010, enrolled 404 patients with identical entry criteria [7]. This study included a 26-week main phase followed by a 26-week extension in which tesamorelin-treated responders were re-randomized to continued treatment or placebo to assess durability.

At 26 weeks, VAT reduction was 14.0% with tesamorelin vs. a 4.6% increase with placebo, confirming the magnitude of effect seen in the first trial [7]. The extension phase demonstrated an important clinical point: patients who switched from tesamorelin to placebo at week 26 regained visceral fat, returning to near-baseline levels by week 52. Patients who continued tesamorelin maintained their VAT reduction [7]. This established that tesamorelin's effect on visceral fat requires ongoing therapy.

The Endocrine Society's 2014 clinical practice guideline on GH use in adults noted: "Tesamorelin has been shown to reduce visceral adiposity in HIV-associated lipodystrophy in two randomized controlled trials with consistent effect sizes" [8].

Safety Profile Across Trials

Pooled safety data from both phase 3 studies (N = 816 combined) showed that tesamorelin was generally well tolerated [1][7]. The most common adverse events in the treatment groups were injection-site reactions (erythema, pruritus, pain) occurring in approximately 8.5% of patients vs. 3.0% on placebo. Arthralgia appeared in 12.5% vs. 8.9%. Peripheral edema occurred in 5.8% vs. 2.1% [9].

The glucose and insulin data required careful interpretation. Fasting glucose rose modestly (a mean increase of approximately 3 mg/dL) in the tesamorelin groups [1]. HbA1c did not change significantly over 26 weeks. Two patients in the tesamorelin group developed new-onset diabetes vs. one in placebo across pooled trials, a difference that was not statistically significant [9]. The FDA label includes a precaution about glucose monitoring, reflecting the known diabetogenic potential of GH-axis stimulation.

IGF-1 elevations were expected and monitored. Mean IGF-1 levels rose above the upper limit of normal in approximately 47% of tesamorelin patients. The clinical significance of sustained IGF-1 elevation in HIV patients remains a subject of ongoing surveillance, though no increase in malignancy was observed in trials of up to 52 weeks [9].

Tesamorelin is contraindicated in pregnancy (Category X), in patients with active malignancy, and in patients with disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, or pituitary tumor surgery [9].

FDA Regulatory Path and Approval

Theratechnologies submitted the New Drug Application (NDA) to the FDA in late 2009. The Endocrinologic and Metabolic Drugs Advisory Committee reviewed tesamorelin in May 2010. The committee voted 11 to 1 in favor of approval, acknowledging the unmet medical need and the reproducible CT-based efficacy data [10].

The FDA granted approval on November 10, 2010, making Egrifta the first and (as of 2026) only FDA-approved treatment specifically indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [10]. The approval was notable for several reasons. The agency accepted CT-measured VAT reduction as a valid surrogate endpoint, setting a regulatory precedent for body composition trials. The label did not require demonstration of cardiovascular outcome benefit, reflecting the difficulty of running long-duration CV outcome trials in a relatively small patient population.

EMD Serono (now the Healthcare business of Merck KGaA, Darmstadt, Germany) held U.S. commercialization rights through a licensing agreement with Theratechnologies from 2008 to 2014 [11]. After that agreement ended, Theratechnologies assumed direct U.S. commercialization.

Egrifta SV: The Reformulation

The original Egrifta formulation required two-vial reconstitution: a vial of lyophilized tesamorelin powder and a vial of sterile water for injection, mixed before each dose. In November 2019, the FDA approved Egrifta SV (single-vial), a ready-to-reconstitute formulation that eliminated the second vial and could be stored at room temperature (up to 25°C) rather than requiring refrigeration [12].

This mattered for patient adherence. A 2018 survey published in AIDS Research and Therapy found that 34% of patients on injectable HIV therapies cited reconstitution complexity as a barrier to adherence [13]. The single-vial format reduced preparation steps from seven to four. The dose remained 2 mg subcutaneous once daily, and the pharmacokinetic profile was bioequivalent to the original formulation [12].

Mechanism of Action in Detail

Tesamorelin's mechanism follows a defined neuroendocrine cascade. After subcutaneous injection, the peptide enters systemic circulation and binds GHRHR on somatotroph cells in the anterior pituitary gland [4]. GHRHR is a class B G-protein-coupled receptor (GPCR). Tesamorelin binding activates Gsα, stimulating adenylyl cyclase to convert ATP to cyclic AMP. Elevated cAMP activates protein kinase A, which phosphorylates transcription factors (primarily CREB) and opens L-type voltage-gated calcium channels. The calcium influx triggers fusion of GH-containing secretory granules with the cell membrane [5].

The resulting GH pulse acts on hepatocytes to stimulate IGF-1 production and acts on adipocytes directly through the GH receptor. GH activates hormone-sensitive lipase in adipose tissue, promoting triglyceride hydrolysis. Visceral adipocytes express higher densities of GH receptors and beta-adrenergic receptors than subcutaneous adipocytes, which partly explains the preferential reduction in VAT observed in trials [14].

A 2010 analysis of the phase 3 data by Stanley and colleagues found that tesamorelin reduced VAT (measured at L4-L5) without significant reduction in subcutaneous abdominal fat or limb fat [15]. This depot-specific lipolytic effect distinguishes tesamorelin from caloric restriction, which reduces both visceral and subcutaneous fat proportionally.

Current Clinical Position and Ongoing Research

As of 2026, tesamorelin remains the only GHRH analog approved for any indication in the United States. Its use is restricted by the FDA label to HIV-associated lipodystrophy, though off-label prescribing for age-related visceral adiposity and metabolic syndrome occurs in cash-pay clinical settings.

Theratechnologies has explored additional indications. A phase 2 trial (NCT02196831) evaluated tesamorelin for nonalcoholic fatty liver disease (NAFLD) in HIV-positive patients and reported a significant reduction in hepatic fat fraction measured by magnetic resonance spectroscopy (a 37% relative reduction vs. 10% with placebo at 12 months, P = 0.02) [16]. This finding, published by Fourman and colleagues in The Lancet HIV in 2020, opened a potential path toward a second indication, though no phase 3 NAFLD trial has been initiated as of early 2026.

The peptide therapy field has expanded considerably since tesamorelin's approval. Growth hormone secretagogues (GHS) such as ipamorelin and CJC-1295 have gained traction in compounding pharmacy and wellness medicine settings, though none carry FDA approval. Tesamorelin's regulatory status and published efficacy data give it a distinct position: the only GH-axis peptide with FDA approval, randomized controlled trial evidence in a defined population, and a formal safety database exceeding 800 patients across controlled studies.

Prescribers should monitor fasting glucose, HbA1c, and IGF-1 levels at baseline, at 3 months, and every 6 months during tesamorelin therapy, consistent with the FDA-approved labeling and the Endocrine Society's recommendations for GH-axis therapies [8][9].